| Title: |
Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report. |
| Authors: |
Mawet, Marie; Basse, Clémence; Barrois, Mathilde; Gligorov, Joseph; Cadranel, Jacques; Chabbert-Buffet, Nathalie; Selleret, Lise |
| Source: |
Journal of Gynecology Obstetrics and Human Reproduction, 52 (10), 102673 (2023-12) |
| Publisher Information: |
Elsevier Masson s.r.l. |
| Publication Year: |
2023 |
| Collection: |
University of Liège: ORBi (Open Repository and Bibliography) |
| Subject Terms: |
Lorlatinib; lung cancer; pregnancy; tyrosine kinase inhibitor; Protein-Tyrosine Kinases; Anaplastic Lymphoma Kinase; Proto-Oncogene Proteins; Lactams; Macrocyclic; Female; Humans; Adult; Protein-Tyrosine Kinases/genetics; Protein-Tyrosine Kinases/therapeutic use; Pregnancy Trimester; Second; Anaplastic Lymphoma Kinase/genetics; Anaplastic Lymphoma Kinase/therapeutic use; Proto-Oncogene Proteins/genetics; Macrocyclic/pharmacology; Macrocyclic/therapeutic use; Carcinoma; Non-Small-Cell Lung/drug therapy; Non-Small-Cell Lung/genetics; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Non-Small-Cell Lung; Lung Neoplasms; Reproductive Medicine; Obstetrics and Gynecology |
| Description: |
peer reviewed ; Use of Lorlatinib, a third-generation tyrosine kinase inhibitor currently indicated in the treatment of non-small-cell lung cancer (NSCLC) with ALK or ROS1 gene fusion, is formally contra-indicated during pregnancy due to teratogenic effects observed during pre-clinical studies. We report the case of a 38-year-old woman with a ROS1-positive NSCLC, successfully treated with lorlatinib as second line therapy, who became pregnant while on treatment. Due to significant disease progression 12 weeks after lorlatinib stop and the great uncertainty on the pregnancy outcome, she finally decided to interrupt the pregnancy at 22 weeks of gestation. Echography and gross infant examination did not reveal any malformation. Pregnancies occurring under this kind of new oncologic treatment is expected to happen more frequently in the future. It seems therefore important to us to report any information on the topic to increase our level of knowledge and improve decision-making. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISBN: |
978-2-468-78472-2; 2-468-78472-3 |
| ISSN: |
2468-7847 |
| Relation: |
https://api.elsevier.com/content/article/PII:S246878472300140X?httpAccept=text/xml; urn:issn:2468-7847; https://orbi.uliege.be/handle/2268/339853; info:hdl:2268/339853; info:pmid:37777070 |
| DOI: |
10.1016/j.jogoh.2023.102673 |
| Availability: |
https://orbi.uliege.be/handle/2268/339853; https://orbi.uliege.be/bitstream/2268/339853/1/Mawet%20M%20et%20al.%2c%202023%2c%20Second-trimester%20medical%20abortion%20after%20exposure%20to%20lorlatinib%20during%20early%20pregnancy%2c%20a%20case%20report.pdf; https://doi.org/10.1016/j.jogoh.2023.102673 |
| Rights: |
open access ; http://purl.org/coar/access_right/c_abf2 ; info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.F6DC6534 |
| Database: |
BASE |